Bicara expects its current cash reserves, combined with IPO proceeds, to cover its operational expenses and capital requirements through the first half of 2028.
Company Background and Market Strategy
Bicara Therapeutics has raised $353 million since its inception, including a $165 million Series C round in December. Investors include RA Capital Management, Red Tree Venture Capital, Omega Funds, and Biocon Ltd., among others. The company aims to use its IPO to facilitate future access to public equity markets and increase its market visibility.
Bicara will list its shares on the Nasdaq under the ticker symbol BCAX.
